Insight Molecular Diagnostics prices $15.0 million offering as FDA review continues
The Nasdaq company priced an offering of common stock and pre-funded warrants at $1.75 per share, with net proceeds of about $14.0 million, while its De Novo request for GraftAssureDx remains on hold at FDA.
SEC filing (2)